ESTRO 2022 - Abstract Book

S1075

Abstract book

ESTRO 2022

Conclusion In our study there were no statistically significant differences in acute toxicity incidence between fractionation regimens. No differences were observed in terms of acute toxicity grade neither between the two cohorts nor in the subgroups analysis. This is concordant to the results obtained in other retrospective studies. However, clinical trials are needed to prospectively compare standard fractionation vs. hypofractionation and also to compare different hypofractionated regimens. Late toxicity and efficacy are needed to be evaluated. This and other international studies may lay the foundations to develop clinical trials

PO-1276 A review into the radiological features predicting local recurrence post-SABR in patients with NSCLC

K. LEE 1 , T. Le 2 , R. Lim 3 , G. Hanna 4,5 , H. Gee 6,7,8 , S. Vinod 9,10 , S. Dammak 11,12 , D. Palma 13 , A. Ong 1 , R. Yeghiaian-Alvandi 14 , J. Buck 15 , E. Hau 6,16,17 1 Westmead Hospital, Radiation Oncology, Sydney, Australia; 2 Mid North Coast Cancer Institute, Radiation Oncology, Port Macquarie, Australia; 3 Westmead Hospital, Radiology, Sydney, Australia; 4 Peter MacCallum Cancer Centre, Radiation Oncology, Melbourne, Australia; 5 University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia; 6 Sydney West Radiation Oncology Network, Radiation Oncology, Sydney, Australia; 7 Children's Medical Research Institute, Radiation Oncology, Sydney, Australia; 8 The University of Sydney, Medicine, Sydney, Australia; 9 Liverpool Hospital, Cancer Therapy Centre, Sydney, Australia; 10 University of New South Wales, South Western Sydney Clinical School, Sydney, Australia; 11 Western University, School of Biomedical Engineering, London, Canada; 12 Baines Imaging Research Laboratory, London Regional Cancer Program, London, Canada; 13 Western University, Division of Radiation Oncology, London, Canada; 14 Nepean Hospital, Nepean Cancer Care Centre, Sydney, Australia; 15 Nepean Hospital, Medical Oncology, Sydney, Australia; 16 University of Sydney, Westmead Clinical School, Sydney, Australia; 17 Westmead Institute of Medical Research, Radiation Oncology, Sydney, Australia Purpose or Objective Post-treatment surveillance for local recurrence (LR) following SABR can include both FDG-PET and CT. Radiation-induced lung injury (RILI) shares a similar appearance to LR after treatment making the detection of LR on imaging difficult for